Out Of The Pipeline
Out Of The Pipeline
Liraglutide for obesity: New indication
Out Of The Pipeline
Lisdexamfetamine for binge eating disorder: New indication
Out Of The Pipeline
Suvorexant for sleep-onset insomnia or sleep-maintenance insomnia, or both
Out Of The Pipeline
Vortioxetine for major depressive disorder
Out Of The Pipeline
Levomilnacipran for the treatment of major depressive disorder
An SNRI with once-daily dosing, levomilnacipran decreased core symptoms of MDD and was well tolerated.
Out Of The Pipeline
Long-acting injectable aripiprazole for adult schizophrenia
Depot formulation and once-monthly dosing might improve adherence in patients with schizophrenia
Out Of The Pipeline
Inhaled loxapine for agitation
Reformulation allows for direct administration to the lungs, resulting in rapid absorption into systemic circulation
Out Of The Pipeline
Vilazodone for major depressive disorder
Vilazodone improved scores on multiple depression rating scales compared with placebo and was well tolerated
Out Of The Pipeline
Dextromethorphan/quinidine for pseudobulbar affect
The combination of dextromethorphan and quinidine reduced the number of daily PBA episodes in 3 randomized trials
Out Of The Pipeline
Lurasidone for schizophrenia
A new atypical antipsychotic offers once-daily dosing and is well tolerated and considered weight neutral
Out Of The Pipeline
Trazodone extended release for major depressive disorder
Once-daily dosing eliminates peaks and troughs in serum concentration seen with the immediate release formulation